Ozempic vs Wegovy: What's the Difference?
If you've researched GLP-1 medications, you've almost certainly encountered both Ozempic and Wegovy—and understandably wondered why two drugs with the exact same active ingredient carry different brand names and very different price tags. The short answer: FDA approval, dosage, and intended use differ meaningfully. Here's a complete side-by-side comparison.
The Core Similarity: Both Are Semaglutide
Ozempic and Wegovy are both manufactured by Novo Nordisk and both deliver semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide mimics the hormone GLP-1, which is released after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and—critically—signals satiety to the brain. These mechanisms lower blood sugar in diabetics and reduce appetite in everyone who takes it.
FDA Approval: The Key Distinction
- Ozempic — Approved in December 2017 for Type 2 diabetes management. Also has cardiovascular risk reduction approval (SUSTAIN-6 data).
- Wegovy — Approved in June 2021 for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity. Also approved (2024) for reducing cardiovascular events in obese/overweight adults.
This approval distinction matters enormously for insurance coverage. Insurers often require an on-label indication, meaning Ozempic is covered for diabetes and Wegovy is covered (where anti-obesity benefits exist) for weight management.
Dosage Comparison
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Approved indication | Type 2 diabetes | Chronic weight management |
| Starting dose | 0.25 mg/week | 0.25 mg/week |
| Maximum dose | 2 mg/week | 2.4 mg/week |
| Titration period | ~16 weeks to 1 mg | ~16 weeks to 2.4 mg |
| Administration | Once-weekly injection | Once-weekly injection |
| Pen device | Single-dose pen | Single-dose pen |
| Retail price/month | ~$935 | ~$1,350 |
Weight Loss Results
The landmark STEP-1 trial demonstrated that 68 weeks of 2.4 mg semaglutide (Wegovy dose) produced an average body weight reduction of 14.9% versus 2.4% for placebo. Real-world Ozempic off-label weight loss data shows modest results at lower doses, with most patients losing 5–10% of body weight at the 1–2 mg maintenance doses.
The higher 2.4 mg Wegovy dose appears to drive meaningfully greater weight loss than the maximum 2 mg Ozempic dose, though the difference between 2 mg and 2.4 mg is smaller than the difference between lower doses and higher ones.
Side Effects: Are They Different?
Because both drugs are semaglutide, the side effect profiles are nearly identical. Expect:
- Nausea (most common, especially during dose escalation)
- Vomiting and diarrhea
- Constipation
- Abdominal pain
- Headache
- Fatigue
Rare but serious risks—pancreatitis, gallbladder disease, thyroid C-cell tumors (in rodents; human risk unclear), and diabetic retinopathy worsening—apply to both. Wegovy's higher target dose may intensify GI side effects for some patients during titration.
Which Should You Choose?
Choose Ozempic if: You have Type 2 diabetes, your insurance covers it for diabetes, and weight loss is a secondary benefit you'd welcome.
Choose Wegovy if: Weight loss is your primary goal, you have a BMI ≥30 (or ≥27 with comorbidities), and your insurance covers anti-obesity medications.
Always make this decision in partnership with your physician, who can review your full medical history and insurance situation.
Frequently Asked Questions
What is the difference between Ozempic and Wegovy?
Both Ozempic and Wegovy contain semaglutide, the same active ingredient. The key differences are FDA-approved indication (Ozempic for Type 2 diabetes; Wegovy for chronic weight management), maximum dose (Ozempic tops out at 2 mg weekly; Wegovy reaches 2.4 mg weekly), and insurance coverage patterns.
Can I use Ozempic instead of Wegovy for weight loss?
Some physicians prescribe Ozempic off-label for weight loss, particularly when Wegovy is unavailable or unaffordable. Clinical data for semaglutide weight loss comes largely from the STEP trials, which used Wegovy doses. Discuss the risks and benefits with your doctor before substituting.
Which causes more weight loss: Ozempic or Wegovy?
Wegovy is generally associated with greater weight loss because it is titrated to a higher maintenance dose (2.4 mg vs. 2 mg). In the STEP-1 trial, participants on 2.4 mg semaglutide lost an average of ~15% of body weight over 68 weeks.
Is Ozempic or Wegovy covered by insurance?
Ozempic is more widely covered for Type 2 diabetes. Wegovy coverage has expanded on commercial plans that include anti-obesity benefits, but Medicare traditionally excluded weight-loss drugs (though this is changing legislatively). Always check your specific plan's formulary.
Are the side effects of Ozempic and Wegovy the same?
Yes, side effect profiles are very similar because both drugs contain semaglutide. The most common are nausea, vomiting, diarrhea, and constipation. Higher Wegovy doses may produce more pronounced gastrointestinal side effects, particularly during titration.
This page is for informational purposes only. Consult a licensed healthcare provider before starting or changing any medication. Drug prices and FDA approvals are subject to change.